Akums Drugs and Pharmaceutical Total Assets
Akums Drugs and Pharmaceutical total assets. Based on the latest financial reports, Akums Drugs and Pharmaceutical (AKUMS) holds total assets worth Rs54.47 Billion INR (≈ $589.07 Million USD) as of March 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see AKUMS market cap for the company's overall valuation and market capitalisation.
Total Assets of Akums Drugs and Pharmaceutical (2022–2026)
Total assets of Akums Drugs and Pharmaceutical from 2022 to 2026. This chart illustrates how Akums Drugs and Pharmaceutical's total assets have evolved over time, based on quarterly financial data. See current stock price of Akums Drugs and Pharmaceutical for real-time trading data and today's change.
Akums Drugs and Pharmaceutical - Asset Composition Analysis
Akums Drugs and Pharmaceutical Total Assets Breakdown (March 2026)
Akums Drugs and Pharmaceutical total assets breakdown as of March 2026. Akums Drugs and Pharmaceutical's total assets of Rs54.47 Billion consist of 65.4% current assets and 34.7% non-current assets.
| Asset Category | Amount (INR) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | Rs0.00 | 7.1% |
| Accounts Receivable | Rs7.97 Billion | 14.6% |
| Inventory | Rs7.56 Billion | 13.9% |
| Property, Plant & Equipment | Rs0.00 | 0.0% |
| Intangible Assets | Rs62.09 Million | 0.1% |
| Goodwill | Rs20.63 Million | 0.0% |
Asset Composition Trend (2022–2026)
This chart illustrates how Akums Drugs and Pharmaceutical's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. Explore Akums Drugs and Pharmaceutical working capital to net assets to assess how much short-term liquidity the company maintains relative to its equity base.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Akums Drugs and Pharmaceutical's current assets represent 65.4% of total assets in 2026, an increase from 61.6% in 2022.
- Cash Position: Cash and equivalents constituted 7.1% of total assets in 2026, up from 1.8% in 2022.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2022.
- Asset Diversification: The largest asset category is accounts receivable at 14.6% of total assets.
Akums Drugs and Pharmaceutical Competitors by Total Assets
Key competitors of Akums Drugs and Pharmaceutical based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Jiangsu Hengrui Medicine Co Ltd
SHG:600276
|
China | CN¥68.33 Billion |
|
Sandoz Group AG
SW:SDZ
|
Switzerland | CHF22.86 Billion |
|
H Lundbeck A/S
CO:HLUN-B
|
Denmark | Dkr54.01 Billion |
|
Changchun High & New Technology Industries Group Inc
SHE:000661
|
China | CN¥30.77 Billion |
|
Hubei Jumpcan Pharmaceutical Co Ltd
SHG:600566
|
China | CN¥17.01 Billion |
|
Kangmei Pharmaceutical Co Ltd
SHG:600518
|
China | CN¥13.68 Billion |
|
Viyash Scientific Limited
NSE:SEQUENT
|
India | Rs17.26 Billion |
|
Anhui Fengyuan Pharmaceutical Co Ltd
SHE:000153
|
China | CN¥5.11 Billion |
Akums Drugs and Pharmaceutical - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 3.25 | 2.55 | 1.48 |
| Quick Ratio | 2.56 | 1.78 | 1.03 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | Rs24.65 Billion | Rs13.81 Billion | Rs7.29 Billion |
Akums Drugs and Pharmaceutical - Advanced Valuation Insights
This section examines the relationship between Akums Drugs and Pharmaceutical's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 3.37 |
| Latest Market Cap to Assets Ratio | 0.02 |
| Asset Growth Rate (YoY) | 32.4% |
| Total Assets | Rs54.47 Billion |
| Market Capitalization | $1.24 Billion USD |
Valuation Analysis
Below Book Valuation: The market values Akums Drugs and Pharmaceutical's assets below their book value (0.02x), which may indicate investor concerns about asset quality or future growth.
Rapid Asset Growth: Akums Drugs and Pharmaceutical's assets grew by 32.4% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Akums Drugs and Pharmaceutical (2022–2026)
The table below shows the annual total assets of Akums Drugs and Pharmaceutical from 2022 to 2026.
| Year | Total Assets | Change |
|---|---|---|
| 2026-03-31 | Rs54.47 Billion ≈ $589.07 Million |
+32.42% |
| 2025-03-31 | Rs41.13 Billion ≈ $444.85 Million |
+16.98% |
| 2024-03-31 | Rs35.16 Billion ≈ $380.28 Million |
+7.65% |
| 2023-03-31 | Rs32.67 Billion ≈ $353.26 Million |
+6.43% |
| 2022-03-31 | Rs30.69 Billion ≈ $331.91 Million |
-- |
About Akums Drugs and Pharmaceutical
Akums Drugs and Pharmaceuticals Limited manufactures and sells pharmaceutical products and active pharmaceutical ingredients India and internationally. The company provides drugs, ayurvedic, nutraceuticals, food and dietary supplements, derma and cosmetics, healthcare and hospital products, over-the-counter (OTC) products, active pharmaceutical ingredients, excipients, and compounds. It also offe… Read more